Feladilimab

Summary

Feladilimab (CHEMBL4297969) is a phase-3 clinical-stage antibody targeting ICOS; indicated across 3 conditions including neoplasm and head and neck neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Targets: 1 (ICOS)
• Indications: 3 conditions
• Clinical trials: 10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297969
Name	Feladilimab
Type	Antibody
Max phase	3

Also known as: Feladilimab, Gsk 3359609, GSK-3359609, GSK-609, Gsk3359609, GSK3359609, FELADILIMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
ICOS	ICOS (CD278)	Binding	8.87	0%	Q9Y6W8

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): ICOS.

Top Reactome pathways

5 total, by targets touching each:

Pathway	Targets	Genes
PIP3 activates AKT signaling	1	ICOS
Constitutive Signaling by Aberrant PI3K in Cancer	1	ICOS
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	1	ICOS
Nuclear events stimulated by ALK signaling in cancer	1	ICOS
Co-stimulation by ICOS	1	ICOS

Dominant GO biological processes

GO term	Targets
T cell tolerance induction	1
immune response	1
T cell costimulation	1
T follicular helper cell differentiation	1
cell-cell adhesion	1

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	2	MONDO:0005070	EFO:0000616
head and neck neoplasm	2	MONDO:0005586	EFO:0005950
plasma cell myeloma	1	MONDO:0009693	EFO:0001378

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE1/PHASE2	3
PHASE2	3
PHASE3	2
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04128696	PHASE3	TERMINATED	Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT04428333	PHASE3	TERMINATED	Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT04126200	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT07217119	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM
NCT03693612	PHASE1/PHASE2	COMPLETED	GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
NCT03739710	PHASE2	COMPLETED	Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
NCT05553808	PHASE2	COMPLETED	Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1
NCT06790303	PHASE2	TERMINATED	Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2
NCT02723955	PHASE1	COMPLETED	Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
NCT03447314	PHASE1	COMPLETED	Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).